To the Editor: I must respectfully disagree with the recent AHA Scientific Statement on the management of transient ischemic attacks.1 First, the inclusion of the combination antiplatelet agent extended release dipyridamole and aspirin (ERDP/ASA) as a “recommended therapy” is premature. The current data are insufficient to definitively establish that ERDP/ASA offers anything in addition to aspirin alone. Although the results of the ESPS-2 trial2 of ERDP/ASA are encouraging and generate great optimism for this and other combination strategies, serious questions remain. The ESPS-2 results are highly inconsistent with previous data on 5317 patients treated with the combination.3 Although a heterogeneous set of trials, these data were sufficient to all but abandon use of dipyridamole in the 1980s. Further, the high rate of subject dropout,2 the lack of …